AstraZeneca PLC (OTCMKTS:AZNCF – Get Free Report) was the target of a large growth in short interest in September. As of September 15th, there was short interest totalling 42,100 shares, a growth of 352.7% from the August 31st total of 9,300 shares. Based on an average trading volume of 2,800 shares, the days-to-cover ratio is currently 15.0 days.
Institutional Investors Weigh In On AstraZeneca
An institutional investor recently bought a new position in AstraZeneca stock. Kennedy Capital Management LLC bought a new stake in shares of AstraZeneca PLC (OTCMKTS:AZNCF – Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 37,554 shares of the company’s stock, valued at approximately $5,068,000. 40.87% of the stock is owned by hedge funds and other institutional investors.
AstraZeneca Trading Down 3.7 %
Shares of OTCMKTS:AZNCF traded down $5.80 during midday trading on Wednesday, reaching $149.34. 6,361 shares of the company’s stock traded hands, compared to its average volume of 2,880. AstraZeneca has a one year low of $118.16 and a one year high of $175.00. The stock has a 50 day moving average of $162.63 and a 200 day moving average of $152.89.
AstraZeneca Cuts Dividend
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Read More
- Five stocks we like better than AstraZeneca
- Energy and Oil Stocks Explained
- Should You Invest in Treasury Bills?
- The 3 Best Fintech Stocks to Buy Now
- Analysts Think There’s Still Time to Get in on Edgewise, Up 332%
- Transportation Stocks Investing
- 3 Stocks Raising Dividends 4X Higher Than Inflation
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.